



医渡科技 2 月通讯 | 2026 年

## Yidu Tech Events in February 2026

### 集团亮点

#### Business Update

#### 宁夏自治区政协和北京市政协考察团调研医渡科技

##### Delegation from Ningxia CPPCC and Beijing CPPCC Visits Yidu Tech

宁夏回族自治区政协主席陈雍、副主席马秀珍率自治区卫健委、数据局、银川市政府等有关负责人一行到医渡科技考察，并就深化医疗健康领域合作进行座谈交流。北京市政协主席魏小东、副主席郭延红参加考察。医渡科技创始人、董事长宫如璟，联合创始人、CEO 徐济铭等公司管理层热情接待。

考察团对医渡科技的技术实力与创新成果给予肯定，并希望公司能积极赋能行业发展。此次交流为双方探索务实合作奠定了坚实基础。医渡科技愿携手宁夏回族自治区共同探索人工智能技术赋能医疗健康产业高质量发展的创新机制，助力“健康中国”与“数字中国”战略在区域的生动实践，为西部地区打造医疗健康科技创新高地贡献力量。

A delegation led by Chen Yong, Chairman of the CPPCC Ningxia Hui Autonomous Region Committee, and Ma Xiuzhen, Vice Chairwoman, visited Yidu Tech for an on-site inspection and exchange. The delegation included officials from the Ningxia Health Commission, Data Administration, and Yinchuan Municipal Government. Wei Xiaodong, Chairman of the CPPCC Beijing Municipal Committee, and Guo Yanhong, Vice Chairwoman, also participated in the visit. Yidu Tech Founder and Chairlady Gong Rujing and Co-founder & CEO Xu Jiming, together with the company's management team, warmly received the delegation.

During the visit, the delegation expressed strong recognition of Yidu Tech's



technological capabilities and innovation achievements, and encouraged the company to continue empowering the development of the healthcare industry. The exchange laid a solid foundation for exploring deeper cooperation in the healthcare sector. Looking ahead, Yidu Tech is committed to working with the Ningxia Hui Autonomous Region to explore innovative mechanisms for leveraging artificial intelligence to advance high-quality development in healthcare. The collaboration will support the regional implementation of the Healthy China and Digital China strategies, and contribute to building a healthcare technology innovation hub in western China.

医渡科技智赋上海健康数据产业高质量发展

## **Yidu Tech Empowers High-Quality Development of Shanghai's Health Data Industry**

上海市健康数据产业协会第一届第二次会员大会暨高质量发展学术大会在沪举办。医渡科技政医事业部高级副总裁袁芳博士受邀参会并在大会上系统阐释了公司真实世界数据智能应用实践。她介绍，医渡科技以真实世界数据为基础，依托“大数据+大模型”双中台，构建了覆盖“诊前一诊中一诊后”全流程的智能体产品体系，并深度融入医院 workflow，实现从智能分诊、辅助诊疗到院外随访的闭环。

面向“十五五”新发展阶段，医渡科技将继续深耕真实世界数据与智能技术，全力推动 AI 与医疗、药械研发、医保支付、健康管理等体系的深度融合。

The 2nd Member Congress of the Shanghai Health Data Industry Association and the Academic Conference on High-Quality Development was recently held in Shanghai. Dr. Yuan Fang, Senior Vice President of Yidu Tech's Government & Healthcare Business, was invited to attend and delivered a keynote presentation on the company's real-world data-driven intelligent applications.

During the conference, Dr. Yuan introduced Yidu Tech's practice in leveraging real-world data. Built on its "Big Data + Large Language Model" dual-platform architecture, the company has developed an intelligent agent product ecosystem covering the entire



healthcare journey—from pre-diagnosis, in-hospital care, to post-treatment management. These solutions are deeply integrated into hospital workflows, enabling a closed-loop system ranging from intelligent triage and clinical decision support to post-discharge follow-up.

Looking ahead to China's upcoming 15th Five-Year Plan development phase, Yidu Tech will continue advancing real-world data and intelligent technologies, further promoting the deep integration of AI with healthcare services, pharmaceutical and medical device R&D, healthcare payment systems, and health management.

医渡科技承办 CMAC RWE 工作组三周年交流活动

### **Yidu Tech Hosts CMAC RWE Working Group 3rd Anniversary Exchange Event**

CMAC 真实世界证据（RWE）工作组成立三周年交流会在医渡科技北京总部举办。本次活动聚焦真实世界数据与证据在药品医保综合价值评价中的实际应用，邀请行业专家解读最新政策指南、分享一线实践经验。会议由 CMAC RWE 工作组主席、强生创新制药医学事务部医学研究和创新部门负责人刘述森主持。CMAC 理事长李景成作开场致词，他特别提到医渡科技在真实世界研究领域拥有扎实的实践积累与技术优势，希望未来能有更多此类高质量的线下活动，深化行业内的实战探讨。

在分享环节中，医渡科技创新医学与真实世界研究副总裁王东生以《真实世界数据赋能医保评价新生态与案例》为题，系统阐述了真实世界证据如何助力医保决策科学化、精细化。通过多个已落地的医保评价案例，讲解了真实世界数据在医保评价中的具体落地方式、研究设计思路和实操难点解决办法，为与会者提供了宝贵的实践参考。

The 3rd Anniversary Exchange Meeting of the CMAC Real-World Evidence (RWE) Working Group was successfully held at Yidu Tech's Beijing headquarters. The event focused on the practical application of real-world data and evidence in the comprehensive value assessment of pharmaceuticals for medical insurance. Industry experts were invited to interpret the latest policy guidelines and share frontline practical experiences. The meeting was chaired by Liu Shusen, Chair of the CMAC RWE



Working Group and Head of Medical Research and Innovation, Medical Affairs, Johnson & Johnson Innovative Medicine. Li Jingcheng, Chairman of CMAC, delivered the opening remarks, highlighting Yidu Tech's solid practical experience and technological strengths in real-world research. He also expressed his expectation for more high-quality offline events to further deepen industry-wide practical discussions. During the sharing session, Wang Dongsheng, Vice President of Innovative Medicine and Real-World Research at Yidu Tech, delivered a presentation titled "Empowering a New Ecosystem for Medical Insurance Evaluation with Real-World Data: Cases and Insights." He systematically elaborated on how real-world evidence can support more scientific and refined decision-making in medical insurance. Through multiple implemented case studies, he illustrated practical approaches, research design methodologies, and solutions to key operational challenges in applying real-world data to insurance evaluation, offering valuable insights for attendees.

## 业务进展

### **Business Progress**

医渡科技携手同济医院攻关胃肠肿瘤 AI 诊疗，成功“揭榜”国家级任务！

### **Yidu Tech Partners with Tongji Hospital to Advance AI-Driven Diagnosis and Treatment of Gastrointestinal Tumors, Selected for National-Level Innovation Task**

医渡科技与华中科技大学同济医学院附属同济医院联合申报的胃肠肿瘤诊疗多模态 AI 数据库项目成功入选国家工信部 2025 年人工智能医疗器械创新任务“揭榜挂帅”名单。该项目旨在构建高质量、标准化的胃肠肿瘤全周期数据平台，并基于此开发覆盖筛查、分型到疗效预测的 AI 辅助诊疗系统，目标直指提升我国胃肠肿瘤的早期发现率和治疗精准度，推动成果转化。



Yidu Tech, in collaboration with Tongji Hospital affiliated with Tongji Medical College of HUST, has successfully been selected for the 2025 "Open Competition Mechanism" Artificial Intelligence Medical Device Innovation Task led by China's Ministry of Industry and Information Technology. The jointly proposed project focuses on building a high-quality, standardized multimodal AI database for gastrointestinal tumor diagnosis and treatment across the full patient journey. Based on this foundation, the team aims to develop an AI-powered clinical decision support system covering screening, classification, and treatment outcome prediction. The project is designed to significantly improve early detection rates and precision treatment of gastrointestinal tumors in China, while accelerating the translation of research outcomes into real-world clinical applications.

医渡科技中标广东省某三甲医院 PIONEER2 CRO 技术服务项目

### **Yidu Tech Wins PIONEER2 CRO Technical Service Project at a Leading Tertiary Hospital in Guangzhou**

医渡科技成功中标广东省某三甲医院 PIONEER2 CRO 技术服务项目。慢性阻塞性肺疾病作为最常见的慢性呼吸系统疾病之一，在我国呈现高患病率、高死亡率和高疾病负担的特征。本项目由呼吸领域知名专家钟院士全程指导，依托前期深度合作所获得的研究团队及资助方阿斯利康（AZ）的高度认可，在项目二期进一步深化合作。医渡科技将充分发挥在真实世界研究及临床项目管理领域的专业能力，全力支持 COPD 领域的临床研究，为提升患者生活质量、减轻疾病负担持续贡献技术力量。

Yidu Tech has won the PIONEER2 CRO technical service project at a leading tertiary hospital in Guangzhou. Chronic obstructive pulmonary disease (COPD), one of the most prevalent chronic respiratory diseases, is associated with high morbidity, mortality, and disease burden in China. The project is guided by Academician Zhong, a leading expert in respiratory medicine, and builds on strong recognition from both



the research team and the sponsor, AstraZeneca, following previous successful collaboration. In Phase II, the partnership will be further deepened. Yidu Tech will leverage its expertise in real-world research and clinical project management to support COPD clinical studies, contributing to improved patient outcomes and reduced disease burden.

医渡科技中标某知名生物医药企业 BGT-004 乳膏治疗特应性皮炎 I b/ II a 期临床研究项目

### **Yidu Tech Wins Clinical Study Project for BGT-004 Cream in Atopic Dermatitis**

医渡科技成功中标某知名生物医药企业 BGT-004 乳膏治疗特应性皮炎 I b/ II a 期临床研究项目。本项目是一项针对全新 GPR84 靶点治疗特应性皮炎的 Ib/II 期研究。医渡科技凭借在竞标过程中展现出的专业技术能力、深厚的临床研究经验以及高效的沟通反馈机制，从众多竞争者中脱颖而出，成功赢得客户信赖。此次中标不仅标志着医渡科技在皮肤疾病领域再获新客户，更实现了对新靶点研究的深入拓展，进一步彰显了公司在创新药临床研究服务领域的优势和专业实力。

Yidu Tech has won the clinical research project for a BGT-004 cream developed by a leading biopharmaceutical company, targeting atopic dermatitis in a Phase Ib/IIa study. This project is a Phase Ib/IIa clinical study investigating a novel GPR84-targeted therapy for the treatment of atopic dermatitis. Leveraging its strong technical expertise, extensive clinical research experience, and efficient communication and feedback mechanisms demonstrated throughout the bidding process, Yidu Tech stood out among multiple competitors and successfully earned the client's trust. This win not only marks Yidu Tech's expansion into a new client partnership in the dermatology field, but also represents a deeper advancement into research on novel therapeutic targets,



further highlighting the company's strengths and professional capabilities in innovative drug clinical research services.

## 集团荣誉

### Honors of Yidu Tech

国家数据局发布“数据要素×”获奖案例集，医渡科技传染病防控优秀实践获收录

#### **Yidu Tech's Infectious Disease Prevention and Control Practice Selected for National "Data Elements ×" Award Case Collection**

国家数据局联合 19 个中央部委共同发布《2025 年“数据要素×”大赛全国总决赛获奖项目案例集》。由海南省卫生健康委员会统计信息中心牵头、医渡科技提供核心技术支撑的“海南自贸港‘外防输入’传染病监测预警”项目，作为医疗健康赛道优秀实践案例成功入选。

China's National Data Administration, in collaboration with 19 central government ministries, has jointly released the 2025 National Finals Award Case Collection of the "Data Elements ×" Competition. The project "Infectious Disease Surveillance and Early Warning for 'Preventing External Importation' in Hainan Free Trade Port", led by the Statistical Information Center of the Hainan Provincial Health Commission and supported by Yidu Tech's core technologies, has been selected as an outstanding practice case in the healthcare track.



图片来源：国家数据局网站

## 投资者交流

### Investor Communication

医渡科技 IRD 出席华创证券策略会，分享 AI 医疗创新实践与行业洞察

### Yidu Tech IRD Attends Hua Chuang Securities Strategy Conference, Sharing AI Healthcare Innovations and Industry Insights

医渡科技投资者关系总监王晓炜女士近日受邀出席由华创证券举办的资本市场交流活动，与多家专业投资机构围绕医疗人工智能发展趋势、行业创新方向及公司业务进展展开深入沟通。会议以“创新引领”为主题，聚焦科技创新驱动产业升级等前沿议题，吸引了来自资本市场与产业界的多方关注。



在交流环节中，医渡科技重点分享了公司在 AI 医疗领域的长期布局及阶段性成果，并就数据智能驱动医疗创新、AI 技术在临床与科研场景中的应用价值等话题与投资机构进行了深入探讨。通过对核心业务模式与发展路径的系统介绍，公司进一步向资本市场传递了清晰的发展思路与增长动能，持续强化投资者对医渡科技创新能力及长期价值的认知。

Ms. Wang Xiaowei, Investor Relations Director of Yidu Tech, was recently invited to attend a capital markets exchange event hosted by Hua Chuang Securities. During the event, she engaged in in-depth discussions with multiple professional investment institutions on the development trends of medical artificial intelligence, directions for industry innovation, and the company's latest business progress. Centered on the theme of "Innovation-Driven Growth," the conference focused on cutting-edge topics such as technology-driven industrial upgrading, attracting broad attention from both the capital markets and industry participants.

During the exchange session, Yidu Tech highlighted its long-term strategic and phased achievements in AI healthcare. The company also engaged with investors on topics including data intelligence-driven healthcare innovation and the value of AI applications in clinical and research settings. Through a systematic introduction of its core business model and development pathway, Yidu Tech further conveyed a clear growth strategy and strong momentum to the capital markets, continuously reinforcing investor confidence in its innovation capabilities and long-term value.